AQR Capital Management
LCTX icon

AQR Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

AQR Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,650
Closed -$19.7K – 3611
2025
Q3 		$19.7K Sell
11,650
-183,733
-94% -$217K ﹤0.01% 3450
2025
Q2 		$177K Buy
195,383
+163,392
+511% +$96.9K ﹤0.01% 3077
2025
Q1 		$14.4K Buy
+31,991
New +$18.8K ﹤0.01% 3136
2022
Q1 		– Sell
-40,688
Closed -$100K – 2253
2021
Q4 		$100K Sell
40,688
-60,239
-60% -$141K ﹤0.01% 2148
2021
Q3 		$254K Buy
+100,927
New +$259K ﹤0.01% 2086
2016
Q2 		– Sell
-11,713
Closed -$29K – 2236
2016
Q1 		$29K Sell
11,713
-31,390
-73% -$70K ﹤0.01% 2202
2015
Q4 		$143K Sell
43,103
-16,050
-27% -$48K ﹤0.01% 2191
2015
Q3 		$143K Buy
59,153
+5,509
+10% +$14.3K ﹤0.01% 2103
2015
Q2 		$157K Buy
+53,644
New +$208K ﹤0.01% 2132

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management's LCTX Position: Q4 2025 in Review

AQR Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 11,650 shares — an estimated $19.7K sold.

AQR Capital Management first reported a position in LCTX in Q2 2015 and held it in 9 quarters. The position peaked at $254K in Q3 2021. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • AQR Capital Management reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 11,650 Lineage Cell Therapeutics shares in Q4 2025, an estimated $19.7K.
  • AQR Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 9 quarters.
  • AQR Capital Management's Lineage Cell Therapeutics position peaked at $254K in Q3 2021.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.